Clinical Performance and Safety of STYLAGE® HydroMax
Launched by LABORATOIRES VIVACY ·
Trial Information
Current as of October 17, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well and how safely a product called STYLAGE® HydroMax works to treat fine, surface-level wrinkles, especially on the cheeks. STYLAGE® HydroMax is a treatment designed to help improve the appearance of aging skin by reducing these small wrinkles, making the skin look smoother and more youthful.
The study is open to adults of all genders who are interested in addressing superficial wrinkles on their face. While the exact age range listed seems unusual, typically, participants would be adults within a standard age range for wrinkle treatment. Those who join the trial can expect to receive the STYLAGE® HydroMax treatment and be monitored to see how well it reduces wrinkles and if there are any side effects. This study is not yet recruiting participants, but it aims to provide more information on the safety and effectiveness of this treatment for people looking to improve the look of their skin as they age.
Gender
ALL
Eligibility criteria
About Laboratoires Vivacy
Laboratoires Vivacy is a distinguished clinical trial sponsor specializing in innovative aesthetic and medical products. With a strong commitment to research and development, the company focuses on creating high-quality dermal fillers and biorevitalization solutions that enhance patient outcomes and satisfaction. Leveraging state-of-the-art technology and a robust scientific framework, Laboratoires Vivacy conducts rigorous clinical trials to ensure the safety and efficacy of its products, contributing significantly to advancements in the field of aesthetic medicine. Through collaboration with healthcare professionals and adherence to the highest regulatory standards, Vivacy strives to deliver transformative solutions that meet the evolving needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Patricia MOREL-MANDRINO, MD
Principal Investigator
Eurofins Dermscan, Villeurbanne, FRANCE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported